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Effect of age and sex on immune
checkpoint expression and kinetics in
human T cells
Rosanne D. Reitsema1*† , Rebeca Hid Cadena2†, Sander H. Nijhof2, Wayel H. Abdulahad1,2, Minke G. Huitema1,
Davy Paap1, Elisabeth Brouwer1, Annemieke M. H. Boots1† and Peter Heeringa2†
Abstract
Background: Immune checkpoints are crucial molecules in maintaining a proper immune balance. Even though age
and sex are known to have effects on the immune system, the interplay between age, sex and immune checkpoint
expression by T cells is not known. The aim of this study was to determine whether age and sex affect immune
checkpoint expression by T cells and if age and sex affect the kinetics of immune checkpoint expression following ex vivo
stimulation. In this study, whole blood samples of 20 healthy young adults (YA, 9 males and 11 females) and 20 healthy
older adults (OA, 9 males and 11 females) were stained for lymphocyte lineage markers and immune checkpoints and
frequencies of CD28+, PD-1+, VISTA+ and CD40L+ T cells were determined. Immune checkpoint expression kinetics were
studied following ex vivo anti-CD3/anti-CD28 stimulation of T cells from young and older healthy adults.
Results: We report an age-associated increase of CD40L + CD4+ and CD40L + CD8+ T-cell frequencies, whereas CD40+
B-cell frequencies were decreased in older adults, suggesting modulation of the CD40L-CD40 interaction with age.
Immune checkpoint expression kinetics revealed differences in magnitude between CD4+ and CD8+ T cells independent
of age and sex. Further analysis of CD4+ T-cell subsets revealed an age-associated decrease of especially PD-1 + CD4+
memory T cells which tracked with the female sex.
Conclusion: Collectively, our results demonstrate that both age and sex modulate expression of immune checkpoints
by human T cells. These findings may have implications for optimising vaccination and immune checkpoint
immunotherapy and move the field towards precision medicine in the management of older patient groups.
Keywords: Immune checkpoints, Age, Sex, T cells, PD-1, CD40L, VISTA, CD28
Background
Age and sex are associated with many changes in im-
mune function and with development of multiple
(auto) inflammatory diseases such as rheumatoid
arthritis, systemic lupus erythematosus (SLE), giant
cell arteritis and polymyalgia rheumatica [1–3]. Major
age-associated changes in the immune system include
a decrease in the number of lymphocytes, especially
naive CD8+ T cells, and a decrease in the diversity of
the T-cell receptor repertoire [4, 5]. In addition,
humoral immunity wanes with ageing, which is pre-
sumably caused by both decreases in B cells and in
the production of high-affinity antibodies [6–8]. Com-
pared to age-related changes, the effect of sex on im-
mune function is less well understood. Nevertheless,
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it is known that there are multiple differences in the
immune system between males and females. In gen-
eral, females show stronger immune responses, in-
cluding stronger T-cell responses, which may lead to
an increased protection against different pathogens [9,
10]. In addition, female sex hormones such as estro-
gen enhance B-cell responses [11]. Consequently, a
more active immune system in females during the re-
productive years might render females prone to the
development of inflammation and autoimmune related
conditions [12].
Immune checkpoints (ICs) are pivotal molecules in
the regulation of the immune response and thus im-
portant when studying age- and sex-associated effects
on the immune system. Several IC molecules are cur-
rently targeted to treat cancer and chronic infectious
diseases. During chronic infection and cancer, T cells
become exhausted, a state of poor effector function,
which can be reversed by immunotherapy via the an-
tagonistic targeting of inhibitory ICs [13]. Unfortu-
nately, by activating the immune system to boost the
immune response to tumour cells, several immune-
related adverse events (irAEs) affecting multiple or-
gans of the body can occur [14]. Among these irAEs,
development of rheumatic diseases has been reported
[15, 16], which underlines the importance of ICs in
inflammatory diseases and adds to the complexity of
IC therapy.
The best studied ICs belong to the so called B7
family, which consists of the co-stimulatory IC CD28
and the co-inhibitory ICs programmed death 1 (PD-1)
and the more recently described V-domain Ig sup-
pressor of T-cell activation (VISTA) [17, 18]. Regard-
ing ageing effects, several studies report on decreased
CD28 expression by CD8+ and to a lesser extent
CD4+ cells of older adults, whereas limited data is
available on effects of age and sex on the expression
of other ICs [4, 19, 20].
The aim of this study was to determine whether
age and sex affect IC expression by T cells and if
age and sex affect the kinetics of IC expression fol-
lowing ex vivo stimulation. To this end, we investi-
gated expression and kinetics of the co-stimulatory
molecules CD28 and CD40L and the co-inhibitory
molecules PD-1 and VISTA on both CD4+ and
CD8+ cells in young and older males and females.
In addition, we investigated IC expression by naive
and memory CD4+ T-cell subsets and CD40 expres-
sion by B cells. Age- and sex- dependent differences
in IC expression may underlie the higher propensity
of females to develop inflammation and autoimmune
conditions. Furthermore, the knowledge obtained
could be important for optimising current vaccin-
ation and immunotherapies for the ageing world
populations and aid the development of precision
medicine.
Results
Effects of age and sex on numbers of circulating immune
cells
As ageing has been associated with alterations in periph-
eral blood immune cell counts, we first determined ab-
solute leukocyte counts in peripheral blood samples of
healthy young adults (YA, n = 14) and older adults (OA,
n = 14) by TruCount (Fig. 1, Additional Table S1). We
confirmed decreases of total lymphocyte numbers in OA
(p = 0.039). Furthermore, total T-cell (CD3+) numbers
tended to be decreased in OA (p = 0.079) which was
mainly due to decreases in CD8+ (p = 0.017) but not
CD4+ cells. In addition, B-cell numbers were decreased
in OA (p = 0.004). No statistical differences in immune
cell numbers were detected between males and females
(Additional Fig. S1).
Next, whole blood staining of CD4+ cells in 20 YA and
20 OA employing CD4, CD45RA and CD25 revealed in-
creased ratios of memory over naive T cells in the older
group, as OA had a higher frequency of memory CD4+
cells (CD45RA-) than YA (p = 0.028) (Additional Fig.
S2A). Of note, the selected markers (CD45RA and CD25)
chosen to analyse naive and memory CD4+ T-cell subsets
according to the Miyara classification [21], do not allow
an accurate analysis of naive and memory CD8 subsets.
As expected, more OA were cytomegalovirus (CMV)
positive compared to YA (16/20 and 6/19, respectively,
Additional Table S1). Taken together, our data confirm
previously reported age-induced differences in immune
composition and CMV serostatus. Furthermore, no dif-
ferences in ratios of memory over naive CD4+ T cells
were detected between CMV+ and CMV- YA and OA
(Additional Fig. S2B).
Effects of age on immune checkpoint expression in
circulating CD4+ and CD8+ T cells
To study the effects of age on IC expression, frequen-
cies of CD28+, PD-1+, VISTA+ and CD40L+ T cells
were first determined within total circulating CD4+
and CD8+ cells of YA (n = 20) and OA (n = 20). Age
did not have a strong effect on frequencies of CD28+,
PD-1+ and VISTA+ cells within both CD4+ and
CD8+ T-cell populations (Fig. 2a-b). However, age
clearly affected CD40L expression, as an increase in
the frequency of CD40L+ cells within both CD4+ and
CD8+ cells was observed in OA (p < 0.001).
Effects of age on CD40 expression by circulating B cells
CD40/CD40L interactions are important in T-and B-
cell crosstalk. As we observed an increase in
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frequencies of CD40L + CD4+ cells in OA, we won-
dered how age would affect CD40 expression by B
cells. Interestingly, we found a decrease in frequencies
of CD40+ B cells in OA (p = 0.042, n = 16) (Fig. 2c).
Thus, age had opposite effects on CD40L and CD40
expression by T cells and B cells, respectively.
Effects of age on immune checkpoint kinetics in
circulating CD4+ and CD8+ T cells
To investigate whether the capacity to express CD40L,
PD-1 and VISTA by CD4+ and CD8+ T cells upon
stimulation is affected by age, we stimulated enriched
CD4+ and CD8+ T-cell populations with anti-CD3 and
anti-CD28 stimulation beads ex vivo and assessed frequen-
cies of IC positive cells at 1, 2, 3, 4, 18, 42, 66 and 90 h
thereafter. Figure 3a illustrates the kinetics of checkpoint
expression by CD4+ cells of YA and OA. First, CD40L was
most promptly upregulated and peaked at 18 h after stimu-
lation with more than 60% of CD40L +CD4+ T cells. Here-
after, frequencies gradually declined with approximately
30–40% of CD4+ T cells remaining positive for CD40L at
90 h after stimulation. The kinetics of PD-1+ frequencies
showed a somewhat slower increase and reached a plateau
at around 40% of PD1 +CD4+ cells. The frequency of
VISTA+ cells did not follow a clear pattern of upregulation
after stimulation and remained low (< 10%) compared to
the other ICs. No effects of age on IC expression kinetics
by stimulated CD4+ cells were observed. In addition, we
did not detect differences between males and females on
the kinetics of IC expression (Additional Fig. S3). This
would suggest that the capacity of T cells to upregulate im-
mune checkpoints after antigenic stimulation is stable over
age and comparable between males and females.
The pattern of IC upregulation by CD8+ cells was less
pronounced than seen with the CD4+ subset (Fig. 3b).
Also, whereas the frequency of PD-1+ cells within CD4+
cells stabilized after 42 h of stimulation, their frequencies
within CD8+ T cells decreased somewhat after 42 h. Of
note, CD8+ cells did not seem to upregulate VISTA at all.
Effects of age on IC expression by CD4+ T-cell
differentiation subsets
Our data confirmed elevated memory/naive T-cell ratios
in OA. Given these compositional changes, we analysed
the expression of ICs on naive (CD45RA+) and memory
(CD45RA-) CD4+ T cells. Here we found elevated fre-
quencies of CD40L + CD4+ in both total naive and
memory T cells (p < 0.001) in OA. Interestingly, subset-
ting of CD4 in naive and memory subsets, revealed that
frequencies of PD-1+ cells were higher in total naive
CD4+ (p = 0.034) in OA, whereas frequencies of PD-1+
cells were lower in total memory CD4+ cells (p = 0.04)
in OA. In contrast, age did not seem to affect frequen-
cies of CD28+ and VISTA+ cells among total naive and
memory cells (Fig. 4). Age-associated effects on PD-1
and CD40L expression by naive and memory CD4+ T
cells were not affected by CMV serostatus (Additional
Fig. S4). No statistical differences in PD-1 expression
were found after stratifying by CMV status, which is
likely a result of a loss of power due to the small number
Fig. 1 Absolute cell counts in peripheral blood of young and older healthy adults. Absolute cell counts of total lymphocytes, CD3+, CD4+ and CD8+ T
cells, NK cells and B cells were determined by TruCount. Horizontal bars reflect median values. Light pink areas represent values outside the reference
range. Reference values were provided by the department of Laboratory Medicine (UMCG). Solid circles represent females and open circles represent
males. The Mann-Whitney U test was used for comparisons between young (YA, n = 14) and older adults (OA, n = 14). P-values are indicated in the graphs
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of adults in both the CMV+ YA (n = 6) and CMV- OA
(n = 4) groups. However, a similar pattern of expression
was observed in CMV+ and CMV- YA and OA.
Next, we further subdivided naive and memory sub-
sets based on CD25 expression using the Miyara clas-
sification to gain additional insight in IC expression
by conventional memory and naive (fractions 4–7)
versus regulatory CD4+ T subsets (fractions 1–3,
Additional Fig. S5). In line with previous studies, our
further subtyping of naive and memory fractions
showed a lower frequency of cells in fraction 6 (p <
0.001, naive CD25- T cells) and a higher frequency of
cells in the ageing-associated fraction 7 (p < 0.001,
naive CD25dim T cells) in OA [21, 22] (Additional
Fig. S6). Interestingly, the higher frequencies of
CD40L + CD4+ cells of OA (Fig. 2) were characteristic
of all CD4+ fractions (Additional Fig. S7).
As we found that PD-1 frequencies were increased in
naive CD4+ T cells but decreased in memory CD4+ T
cells, further subsetting revealed that the increase in
naive PD-1 + CD4+ T cells was mainly due to increased
frequencies of PD-1+ cells in the naive/resting Treg sub-
set (fraction 1, p = 0.003, CD25int Treg). In addition, we
found increased PD-1+ frequencies in the conventional
naive CD4+ subset (fraction 6, p = 0.021, CD25-),
whereas PD-1 frequencies were decreased in the ageing-
associated naive CD25dim subset (fraction 7, p = 0.005)
in OA (Fig. 5, upper panel).
The decrease of PD-1 frequencies in memory CD4+
T cells was characteristic of all CD25+ memory sub-
sets (fraction 4, (p = 0.003, CD25dim) and fraction 3
(p = 0.011, non-suppressive Tregs, CD25 int), includ-
ing Tregs fraction 2 (p = 0.038, activated Tregs,
CD25high Tregs)), whereas no differences in PD-1 fre-
quencies were found in fraction 5 (p = 0.799, CD25-)
(Fig. 5, lower panel).
Collectively, a more detailed analysis of CD4+ T-cell dif-
ferentiation subsets revealed age- associated modulation
Fig. 2 Immune checkpoint expression frequencies within CD4+ and CD8+ cells and B cells of young and older adults. Age effects on immune
checkpoint expression were determined by flow cytometric staining of whole blood from young and older adults. Graphs represent percentages
of CD28+, PD-1+, VISTA+ and CD40L+ cells within total CD4+ (a) and CD8+ T cells (b) and CD40+ cells within total B cells (c). Open and closed
circles represent males and females, respectively. Open and closed triangles represent males (n = 2) and females (n = 2), respectively, that were
65 years of age or younger in the OA group. Horizontal bars reflect median percentages. The Mann-Whitney U test was used for comparison
between young (YA, n = 20) and older (OA, n = 20) adults. P-values are indicated in the graphs
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of CD40L and PD-1 expression frequencies among both
conventional and regulatory naive and memory subsets.
Effects of sex on immune checkpoint expression by
circulating CD4+ and CD8+ T cells
Sex effects on IC expression were determined by com-
paring IC expression by CD4+ and CD8+ cells between
males and females. Sex did not affect CD28, VISTA and
CD40L expression frequencies within total CD4+ and
CD8+ cells nor PD-1+ frequencies within CD8+ cells.
The frequencies of PD-1 expressing CD4+ T cells, how-
ever, were found to be decreased in females (p = 0.042)
(Fig. 6). Next, when we compared effects of sex within
each age group, lower frequencies of PD-1+ cells were
detected in older females compared to older males (p =
0.038). Further subsetting based on CD45RA expression
revealed that older females had lower frequencies of PD-
1 + CD4+ memory cells (p = 0.046), whereas PD-1+
frequencies among CD4+ naive cells were comparable be-
tween older males and females (Additional Fig. S8). We
also assessed interaction effects between age and sex re-
garding CD28, VISTA and CD40L expression but found
no significant interaction effects in any CD4+ T cell subset
and in total CD8+ T cells (Additional Table S3).
Next, we compared the frequencies of PD-1+ cells be-
tween older males and females following further CD4 sub-
setting (Fig. 7). Indeed, no differences in PD-1+ frequencies
among the naive fractions were noted. The lower frequen-
cies of total PD-1 +CD4+ memory cells in older females,
however, were due to lower frequencies in fraction 5 (p =
0.038), 4 (p = 0.020) and the non-suppressive Treg memory
fraction 3 (p = 0.031). Fraction 2, comprising activated
Tregs, was the only memory fraction in which PD-1 expres-
sion did not differ between the sexes. Therefore, the de-
crease of PD-1+ frequencies among cells in fraction 2 in
OA (Fig. 5), is solely an effect of age, rather than sex.
Fig. 3 Kinetics of immune checkpoint expression. T cells were stimulated and immune checkpoint expression was measured at several time
points thereafter. Graphs illustrate median percentages of CD40L, PD-1 and VISTA in total CD4+ cells (a) and CD8+ cells (b) at indicated time
points (n = 10 young and 10 older adults). Blue and orange solid lines represent the median expression percentages of young (YA) and older
adults (OA), respectively. Dotted blue and orange lines represent unstimulated cells. Error bars indicate interquartile range
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As our subsetting analysis had also revealed decreases
of PD-1+ frequencies in memory CD4+ CD25dim cells
(fraction 4) and the non-suppressive Tregs (fraction 3)
in OA compared to YA, we aimed to assess whether the
age-associated decrease in these fractions is solely
dependent on female sex. To this end, we assessed
whether PD-1 expression was different between young
and older females. Indeed, the age-associated decline in
PD-1 frequencies in fractions 3 and 4 was found to asso-
ciate with female, but not male, sex (fraction 3, p = 0.004
and fraction 4, p = 0.003, Fig. 7b-c).
Taken together, our data reveal an age- associated de-
cline of PD-1 + CD4+ frequencies within defined mem-
ory subsets of older females.
Discussion
In this study we show that both age and sex modulate
expression of ICs by human T cells. More specifically,
our study revealed an age-associated increase of
CD40L + CD4+ T-cell frequencies and an age-associated
decline of PD-1 + CD4+ memory T-cell frequencies in
older females. The latter finding may aid the optimisa-
tion of PD-1 targeted immunotherapy and help the im-
plementation of precision medicine in management of
this vulnerable patient group.
By measuring IC expression within defined subsets of
conventional and regulatory CD4+ T cells, we found that
PD-1 expression on CD4+ memory cells is affected by
both age and sex. More specifically, PD-1 expression fre-
quencies among defined subsets of memory CD4+ cells
were decreased upon age and were lower in older females
than in older males. The observed effects of age on the
non-suppressive Tregs (fraction 3) and the conventional
memory CD25dim CD4+ T cells (fraction 4) can be attrib-
uted solely to the decrease in PD-1 + CD4+ memory T-
cell frequencies in older females. Previously, we reported
on higher frequencies of PD-1-expressing CD4+ T cells in
young, but not old patients with metastatic melanoma,
data consistent with the current finding albeit that effects
of sex were not documented [23].
PD-1 has been identified as a crucial IC in the regulation
of the immune system and more specifically in preventing
auto-immune diseases [24]. The rationale for this associ-
ation arose from observations in PD-1 knockout mice,
since these mice were prone to develop auto-immune dis-
eases [25, 26]. Furthermore, blocking PD-1 in an experi-
mental autoimmune encephalomyelitis (EAE) mouse
model resulted in aggravated disease progression [27].
Since the older females in this study likely reached the
post-menopausal status, the observed decrease in PD-1 +
CD4+ frequencies in older females compared to young
Fig. 4 Immune checkpoint expression frequencies among naive and memory CD4+ cells of young and older adults. Age effects on CD28, PD-1,
VISTA and CD40L expression within naive and memory CD4+ T cells were determined by flow cytometric staining of whole blood. Graphs
represent percentages of immune checkpoints within total naive (CD45RA+) and memory (CD45RA-) CD4+ cells. Open and closed circles
respectively represent males and females. Open and closed triangles represent males (n = 2) and females (n = 2), respectively, that were 65 years
of age or younger in the OA group. Horizontal bars reflect median percentages. The Mann-Whitney U test was used for comparison between
young (YA, n = 20) and older (OA, n = 20) adults. P-values are indicated in the graphs
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females, may be explained by a decrease in female sex hor-
mones such as estrogens. Interestingly, previous studies in
mice have suggested an effect of estrogen on PD-1 expres-
sion by Tregs. Firstly, estrogen (17-beta-estradiol) treat-
ment increased intracellular PD-1 expression in Treg cells
in mice, whereas oestrogen receptor knockout mice had
reduced PD-1 expression and reduced Treg suppression
[28]. Secondly, the PD-1 induction in the Treg compart-
ment by estrogen correlated with better suppression and
hence EAE protection whereas Treg deficient mice ap-
peared to be unprotected against EAE. Lastly, estrogen re-
duced IL-17 levels in immunized mice, whereas estrogen
did not reduce IL-17 levels in PD-1 deficient mice. These
results suggest suppression of IL-17 by estrogen-induced
PD-1 + Tregs [29].
Thus, the mouse studies show that PD-1 expression by
Tregs can be modulated by estrogens with clear conse-
quences for experimental autoimmunity. It remains to
be elucidated if female sex hormones modulate PD-1 ex-
pression in humans and if this is limited to the Treg
compartment. Additionally, other (hormonal) factors are
likely involved in the regulation of PD-1 expression as
well, as we did not observe lower PD-1 frequencies
among CD4+ T cells from older males. Nevertheless,
some auto-inflammatory diseases such as giant cell ar-
teritis, a large vessel vasculitis typically affecting older fe-
males, and late-onset rheumatoid arthritis could be
related to a post-menopausal decrease in PD-1 expres-
sion. Clearly, this will require further dedicated studies.
Importantly, age- and sex-associated differences in
PD-1 expression frequencies could have implications for
PD-1 blockade therapies in cancer. These therapies typ-
ically reverse the state of exhaustion of tumour specific
effector T cells. Several papers have reviewed the efficacy
of PD-1 blocking therapies in clinical trials having in-
cluded older adults and found contradictory and incon-
sistent results. For some cancers such as head and neck,
non-small cell lung cancer and metastatic renal cell car-
cinoma, the efficacy of IC-blocking therapies in older
adults seemed to be decreased [30], but often no age-
Fig. 5 PD-1 expression frequencies among CD4+ differentiation subsets of young and older adults. Age effects on PD-1 expression were
determined by flow cytometric staining of whole blood according to the Miyara classification employing CD45RA and CD25 [21, 22]. By staining
for CD45RA and CD25 expression, the following seven fractions were distinguished: Memory CD25- (fraction 5), Memory CD25dim (fraction 4),
Memory CD25int Treg (fraction 3), Memory CD25high Treg (fraction 2), Naive CD25- (fraction 6), CD25dim (fraction 7) and Naive CD25int Treg
(fraction 1). Graphs represent percentages of PD-1+ cells within the seven different naive and memory conventional and regulatory CD4+
fractions. Dashed line divides conventional memory and naive fractions from regulatory fractions. Open and closed circles respectively represent
males and females. Horizontal bars reflect median percentages. Open and closed triangles represent males (n = 2) and females (n = 2),
respectively, that were 65 years of age or younger in the OA group. The Mann-Whitney U test was used for comparison between young (YA, n =
20) and older (OA, n = 20) adults. P-values are indicated in the graphs
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associated differences were found [31, 32]. In addition,
some studies noted increased efficacies with ageing [33].
Overall, it should be appreciated that older patients (>
65 years) have been under-represented in many clinical
trials, and that those who were included may not be rep-
resentative of the older population in general [30]. In
addition, a meta-analysis addressing sex-dependent ef-
fects of IC-blocking therapy revealed a lower efficacy in
women than in men. Here, differences between young
and older patients were not addressed [34]. Together,
these findings indicate that more studies are needed to
determine the efficacy and toxicity of IC-blocking ther-
apy in young and older males and females.
Frequencies of CD40L+ T cells were impacted by age
as well. Although differences in frequencies of CD40L+
cells between young and older adults appeared to be
subtle, the increase in the older group was consistent
and seen in every subset of CD4+ T cells. As CD40L
pairs with CD40 in T-cell/B-cell interactions, an in-
creased expression of CD40L could lead to an increased
B-cell response [35, 36]. This, however, is contradictory
with the notion that the humoral response wanes with
ageing. Indeed, the observed increase in CD40L+ T-cell
frequencies was paralleled by a decrease in CD40+ B-
cell frequencies in older adults, suggesting that upregu-
lation of CD40L may be a compensatory mechanism.
CD40L/CD40 interactions have been found to be
important in autoimmune diseases such as SLE. In SLE,
CD40L expression is increased on circulating B- and T
cells but data on CD40 expression levels have not been
reported [37]. Elevated CD40L levels have been sug-
gested to cause an amplification of the immune re-
sponse and an increase in autoantibodies [37–39].
Whether the observed increase of CD40L + CD4+ T
cells in older adults is solely a compensatory mechan-
ism or has consequences for immune function and
humoral responses remains to be further investigated.
The kinetics of IC-expression appeared to be different
between CD4+ and CD8+ cells. In line with our observa-
tions, an in vitro study performed by Sabins et al.
showed higher PD-1 expression by CD4+ cells than by
CD8+ cells [40]. Although differences were seen in IC-
expression by circulating T cells, the capacity of T cells
to upregulate ICs upon stimulation ex vivo appeared to
be unaffected by age and sex.
This study has some limitations. First, we report re-
sults of a relatively small number of healthy donors. Re-
sults in this study should therefore be interpreted with
caution and be seen as a first step towards more infor-
mation on age and sex effects on IC expression and kin-
etics. Secondly, while assessing the kinetics of IC-
expression, we did not determine other characteristics
such as proliferative capacity and cytokine production,
which could have revealed more clues as to how age and
Fig. 6 Effect of sex on CD28, PD-1, VISTA and CD40L expression. Sex effects on IC expression were determined by flow cytometric staining of
whole blood. Graphs show the frequencies of ICs in males and females within total CD4+ fractions (a), and total CD8+ T cells (b). Horizontal bars
reflect median percentages. The Mann-Whitney U test was used for comparison between two groups. P-values are indicated in the graphs
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sex affect T-cell function. Furthermore, it remains to be
established if the decrease in PD-1-expressing CD4+
memory T cell frequencies as seen in older females
translates to T cell functional changes such as a poten-
tial increase in proliferative capacity. Thirdly, our study
was not designed to conclude on the effects of CMV ser-
ostatus on T-cell IC expression, but we were able to ex-
clude CMV carriage as a confounder in our study, as
similar patterns were observed in young and older
CMV+ and CMV- donors. Furthermore, we did not ob-
serve a decline in CD28 frequencies upon age which was
expected for at least the CD8 population [20]. One ex-
planation could be that four of our OA volunteers were
relatively young (between 54 and 65) and had relatively
high CD28+ frequencies among CD4+ and CD8+ T cells
which may have skewed the data. Lastly, our methods
did not allow for accurate analysis of the average per cell
IC-expression (MFI), which could give additional infor-
mation when analysing the effects of combined positive
and negative IC expression.
Conclusions
In this study, we provide evidence that both age and sex
modulate expression of ICs by human T cells. Our study
revealed an age-associated increase of CD40L + CD4+ T-
cell frequencies and an age-associated decrease of
CD40+ B-cell frequencies, suggesting modulation of the
CD40L-CD40 interaction with age. Importantly, we doc-
umented an age-associated decline of PD-1 + CD4+
memory T cells in older females.
Fig. 7 Effect of sex on PD-1 expression frequencies. Sex effects on PD-1 expression were determined by flow cytometric staining of whole blood.
Graphs show the frequencies of PD-1+ cells in older males and females within different CD4+ fractions (a), and in young and older males and
females in fraction 3 (b) and fraction 4 (c). Horizontal bars reflect median percentages. Dashed line divides conventional memory and naive
fractions from regulatory fractions. For the comparison of 4 groups, a Kruskal-Wallis test was performed and found to be statistically significant in
fraction 3 and 4 (p = 0.019 and p = 0.005). Each group consisted of n = 9 (males) and n = 11 (females) participants. The Mann-Whitney U test was
used for comparison between two groups. P-values are indicated in the graphs
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We hope that our findings will prompt further re-
search as more knowledge may aid the optimisation of
vaccination and targeted immunotherapy and move the




To study the effect of age and sex on immune check-
point expression, 20 healthy young adults (YA, median
age and range in years: 26 (20–31), male/ female ratio 9/
11) and 20 healthy older adults (OA, median age and
range in years: 72 (54–86), male/female ratio 9/11) were
enrolled in this study (Additional Table S1). Since CMV
serostatus has known effects on immune function and as
CMV seropositivity increases with age [41], CMV seros-
tatus was determined in all participants as described be-
fore [42]. CD40 expression by B cells was measured in
all 20 YA and in 16 of the 20 OA. The kinetics of im-
mune checkpoint expression was determined in a subset
of donors consisting of 10 healthy young and 10 healthy
older adults (median age and range in years YA: 27 (20–
31) and OA: 72 (63–83)), each group consisting of 5
males and 5 females (Additional Table S1).
The participants’ health status was confirmed by a clin-
ician through questionnaires in young donors and by
physical examination, lab tests and questionnaires in older
adults. Donors need to fulfil the adapted SENIEUR criteria
for health status [43]. Volunteers who were diagnosed
with inflammatory or infectious conditions or treated with
immunomodulatory drugs were not included. The consti-
tutional review board of the UMCG approved this study
(METc2012/375) and all donors gave their written in-
formed consent prior to blood withdrawal.
Quantification of leukocytes
Absolute leukocyte counts of the majority of donors (YA:
n = 14, median age and range in years: 26 (30–31) OA:
n = 14, median age and range in years: 74 (57–86)) were
measured in EDTA blood according to the MultiTest Tru-
Count method (BD Biosciences, Durham, NC, USA) ac-
cording to the manufacturer’s instructions. When
absolute counts of an individual donor were measured on
multiple days or when the individual donor’s age differed
among the different experiments, the absolute counts and
ages were averaged (Additional Table S1).
Immune checkpoint expression by whole blood immune
cells
To measure IC expression on circulating immune cells,
fresh blood collected in EDTA tubes was washed twice
with PBS and stained with monoclonal antibodies detect-
ing CD3, CD4, CD45RA, CD25, CD19, CD28, PD-1,
VISTA, CD40 and CD40L for 15min (Additional Table
S2). After surface staining, cells were fixed and red blood
cells were lysed with FACS lysing solution (BD Biosciences,
1:10 dilution). Samples were measured on a BD LSR-II
flow cytometer. Setting of gates was determined by isotype
controls and IC expression was presented as the percent-
age of positive cells within CD4+ and CD8+ T cells and
CD19+ B cells. The use of isotype controls for setting gates
was assessed and confirmed by fluorescence minus one
controls. CD4+ cells were further subclassified into seven
fractions by virtue of CD45RA and CD25 expression, based
on the classification criteria reported by Miyara et al.
(2009) and adapted by van der Geest et al. (2014) (Add-
itional Fig. S5) [21, 22]. This method allowed the classifica-
tion of naive and memory CD4+ T cells as CD45RA+ and
CD45RA-, respectively. In addition, CD25 allowed for sub-
setting of resting and activated conventional and regulatory
naive and memory subsets. Fraction 1, 2 and 3 identify
resting/naive Tregs, activated/memory Tregs and non-
suppressive or cytokine secreting Tregs, respectively. Frac-
tion 4 and 5 comprise conventional memory cells with dim
CD25 and memory cells lacking CD25 expression, respect-
ively. Fraction 6 and 7 comprise conventional naive cells
and age-associated naive CD25dim T cells, respectively.
Kinetics of immune checkpoint expression ex vivo
Expression kinetics were determined by measuring ICs at
defined time points after T-cell stimulation ex vivo. Briefly,
peripheral blood mononuclear cells were isolated from
blood collected in heparin tubes by density gradient cen-
trifugation using Lymphoprep (Alere Technologies AS,
Oslo, Norway). Next, T cells were isolated by negative se-
lection using the MagniSort Human T cell Enrichment
Kit (Thermo Fisher Scientific, Waltham, MA., USA) or
the EasySep™ Human T cell isolation kit (Stemcell Tech-
nologies, Vancouver, Canada) (results were found to be
similar for both kits, purity ≥92%) according to manufac-
turer’s instructions. After T-cell enrichment, 0.5 × 106 T
cells were added to 1mL of Roswell Park Memorial Insti-
tute (RPMI) culture medium with HEPES and L-
Glutamine (Lonza, Basel, Switzerland) supplemented with
gentamycin (Lonza), in round-bottomed polypropylene
tubes. Gibco Dynabeads™ Human T-activator anti-CD3/
anti-CD28 (ThermoFisher, Waltham USA) were added to
T cells in a ratio of 1:5. Stimulated T cells were then incu-
bated at 37 °C, 5% CO2 and collected after 1,2,3,4, 18, 42,
66 and 90 h and stained for CD8, CD45RA, CD25, PD-1,
VISTA, and CD40L. In parallel, unstimulated T cells were
also assessed for the same ICs including CD28 at each
time point (See additional Table 2 for the antibodies
used). Staining was performed as described above.
Data analysis and statistics
Flow cytometry data was analysed with Kaluza Analysis
Software (Beckman Coulter, California, USA) and graphs
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were created with GraphPad Prism 7 (GraphPad Soft-
ware, San Diego, USA). Two-tailed Kruskal-Wallis tests
were performed when multiple groups were compared
and Mann-Whitney U tests for comparing two groups.
Interaction effects of age and sex were explored via fac-
torial ANOVA. All results were considered statistically
significant when p < 0.05.
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